Kura Oncology Inc
KURA
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
94% upsideUndervalued by 94% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $905.50 Million |
|---|---|
| Enterprise Value | $938.39 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.18 |
| Beta | 0.32 |
| Outstanding Shares | 88,610,000 |
Return
| Return on Equity | -273.05% |
|---|---|
| Return on Assets | -45.14% |
| Return on Invested Capital | -57.70% |
Valuation & Multiples
| P/E Ratio | -3.07 |
|---|---|
| PEG | -11.08 |
| Price to Sales | - |
| Price to Book Ratio | 8.66 |
| Enterprise Value to Revenue | 13.1 |
| Enterprise Value to EBIT | -2.95 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.67 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9991▲ 29.63% |
|---|---|
| Total Calls | 217,400▼ 26.40% |
| Total Puts | 217,200▲ 4.62% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 95.83%▼ 1.56% |
|---|---|
| Total Invested | $686.10M▼ 22.73% |
| Investors Holding | 224▲ 3.00% |
ESG Score
No data
About Kura Oncology Inc
CEO: Troy Wilson Relevant Senate Committees
Provides crucial non-partisan analysis and 'scoring' for all tax legislation, directly influencing corporate tax structures, R&D credits, and overall profitability for pharmaceutical companies.
Controls tax policy (influencing corporate profitability), trade (affecting global supply chains), and entitlement spending like Medicare (a major drug purchaser and price setter).
Allocates federal funding to agencies like NIH (research), FDA (regulatory oversight), and VA (drug procurement), directly impacting the financial landscape for pharmaceutical companies.
Directly regulates the FDA (drug approval process), NIH (research funding), and influences labor laws, all of which are central to a pharmaceutical company's operations and success.
Oversees intellectual property (patents), which is crucial for pharmaceutical drug development and market exclusivity, and antitrust enforcement.
Investigates critical issues like drug pricing and access for older Americans, creating significant political and reputational risk for pharmaceutical companies.
Regulates the financial system (SEC) which impacts Kura Oncology as a publicly traded company, affecting capital raising, disclosure requirements, and investor relations.
Oversees the Department of Veterans Affairs, a significant purchaser of pharmaceuticals. Its funding decisions directly impact demand and reimbursement for drugs.